FDA Inspection
Regeneron Pharmaceuticals IncRegeneron Pharmaceuticals Inc – FDA Inspection, Feb 16, 2024
Record Details
This FDA Inspection record concerns Regeneron Pharmaceuticals Inc, with an inspection on February 16, 2024, issued by the New York District Office, covering human drugs.
- Office
- New York District Office
- Person
- Lindsey J. Brown (Issuing Officer)
View Company Profile
ID · be92bc21-d599-4a82-9b9d-dde944acebd3
Inspection Facts
- Inspection number
- 1239760
- FDA center
- Human Drugs
- Outcome
- Form 483 issued
Other FDA inspections of Regeneron Pharmaceuticals Inc
12| Date | Classification | Office | Project area |
|---|---|---|---|
| March 22, 2024 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| October 25, 2021 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| October 18, 2019 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| June 8, 2018 | Not classified | New York District Office | |
| October 5, 2017 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Regeneron Pharmaceuticals Inc
- FDA Inspection 1230565 - 2024-03-22
- FDA Inspection 1155063 - 2021-10-25
- FDA Inspection 1106821 - 2019-10-18
- FDA Inspection 1059234 - 2018-06-08
- FDA Inspection 1030807 - 2017-10-05
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.